

# Arantxa Gonzalez

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/472162/arantxa-gonzalez-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155  
papers

8,971  
citations

52  
h-index

91  
g-index

169  
ext. papers

10,734  
ext. citations

6.8  
avg. IF

5.86  
L-index

#	Paper	IF	Citations
155	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2
154	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1806-1818	12.3	7
153	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart OMics in AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 684-696	9.5	23
152	The Role of Circulating Biomarkers in Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
151	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	1
150	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 268-277	7.9	13
149	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1875-1887	12.3	14
148	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 933-944	12.3	8
147	Identification of sex-specific biomarkers predicting new-onset heart failure. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3512-3520	3.7	1
146	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. <i>Nature Reviews Cardiology</i> , <b>2021</b> , 18, 479-498	14.8	20
145	The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1432-1436	12.3	0
144	Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions. <i>Journal of Cardiovascular Pharmacology</i> , <b>2021</b> , 78, e703-e713	3.1	1
143	A novel treatment for heart failure targets myocardial fibrosis. <i>Nature Medicine</i> , <b>2021</b> , 27, 1343-1344	50.5	2
142	Serum and urinary biomarkers of collagen type-I turnover predict prognosis in patients with heart failure. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e267	5.7	3
141	Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. <i>Basic Research in Cardiology</i> , <b>2020</b> , 115, 39	11.8	39
140	Does Chronic Kidney Disease Facilitate Malignant Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction of Hypertensive Origin?. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	7
139	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1711-1723	12.3	22

138	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. <i>Circulation</i> , <b>2020</b> , 141, 751-767	16.7	27
137	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2020</b> , 73, 835-843	0.7	3
136	Omics phenotyping in heart failure: the next frontier. <i>European Heart Journal</i> , <b>2020</b> , 41, 3477-3484	9.5	21
135	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2204-2218	15.1	18
134	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. <i>Revista Espanola De Cardiologia</i> , <b>2020</b> , 73, 248-254	1.5	4
133	Interacción cardiorenal y evolución de la insuficiencia cardíaca. ¿Tiene un papel la proteína de unión del factor de crecimiento de tipo insulina 2?. <i>Revista Espanola De Cardiologia</i> , <b>2020</b> , 73, 835-843	1.5	2
132	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , <b>2020</b> , 40, 223-236	1.5	6
131	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2020</b> , 73, 248-254	0.7	3
130	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , <b>2020</b> , 40, 223-236	0.4	2
129	H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts. <i>Clinical Epigenetics</i> , <b>2020</b> , 12, 106	7.7	9
128	The Myocardium in Aortic Stenosis Revisited: More Complex Than Just Myocytes and Interstitial Diffuse Fibrosis. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 2270-2273	8.4	
127	Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 735-744	15.1	17
126	Myocardial fibrosis in asymptomatic and symptomatic chronic severe primary mitral regurgitation and relationship to tissue characterisation and left ventricular function on cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , <b>2020</b> , 22, 86	6.9	4
125	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 22-33	6.1	11
124	Reprint of "The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking". <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118521	4.9	5
123	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. <i>Hypertension</i> , <b>2019</b> , 73, 820-828	8.5	27
122	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005897	7.6	33
121	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2019</b> , 1866, 1421-1432	4.9	29

120	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2019</b> , 30, 1231-1240	2.7	5
119	Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1398-1410	15.1	33
118	Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1795-1806	15.1	52
117	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. <i>Heart</i> , <b>2019</b> , 105, 307-314	5.1	18
116	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. <i>Scientific Reports</i> , <b>2019</b> , 9, 2956	4.9	8
115	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. <i>Hypertension</i> , <b>2019</b> , 73, 602-611	8.5	44
114	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e010430	6	3
113	Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?. <i>American Journal of Hypertension</i> , <b>2019</b> , 32, 15-17	2.3	2
112	Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1696-1706	15.1	204
111	Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 860-871	15.1	152
110	Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. <i>European Heart Journal</i> , <b>2018</b> , 39, 699-709	9.5	112
109	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. <i>Hypertension</i> , <b>2018</b> , 71, 280-288	8.5	90
108	Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1290-1299	12.3	42
107	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. <i>Matrix Biology</i> , <b>2018</b> , 66, 110-124	11.4	25
106	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 139-148	3.7	14
105	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 460-470	12.3	16
104	Immunomodulation by adoptive regulatory T-cell transfer improves Cocksackievirus B3-induced myocarditis. <i>FASEB Journal</i> , <b>2018</b> , 32, fj201701408R	0.9	24
103	Reply: Aortic Stenosis, Left Ventricular Remodeling, and Renin-Angiotensin System Blockade. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2984-2985	15.1	

102	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , <b>2018</b> , 39, 4243-4254	9.5	113
101	Myocardial Remodeling in Hypertension. <i>Hypertension</i> , <b>2018</b> , 72, 549-558	8.5	58
100	Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2017</b> , 70, 832-840	0.7	12
99	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. <i>Scientific Reports</i> , <b>2017</b> , 7, 41865	4.9	17
98	Myocardial fibrosis: biomedical research from bench to bedside. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 177-191	12.3	195
97	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. <i>Scientific Reports</i> , <b>2017</b> , 7, 40696	4.9	30
96	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , <b>2017</b> , 113, 906-914	9.9	13
95	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. <i>Journal of Hypertension</i> , <b>2017</b> , 35, 853-861	1.9	30
94	The long noncoding RNA controls cardiac fibrosis and remodeling. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	167
93	A Urinary Fragment of Mucin-1 Subunit B <sub>s</sub> a Novel Biomarker Associated With Renal Dysfunction in the General Population. <i>Kidney International Reports</i> , <b>2017</b> , 2, 811-820	4.1	16
92	Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients B0 Years With Heart Failure and Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 2042-2048	3	16
91	Papel del colágeno miocárdico en la estenosis aórtica grave con fracción de eyección conservada y síntomas de insuficiencia cardíaca. <i>Revista Espanola De Cardiologia</i> , <b>2017</b> , 70, 832-840	1.5	20
90	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. <i>Scientific Reports</i> , <b>2017</b> , 7, 16042	4.9	19
89	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. <i>Open Heart</i> , <b>2017</b> , 4, e000615	3	15
88	The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes. <i>Medical Clinics of North America</i> , <b>2017</b> , 101, 43-52	7	14
87	Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. <i>Clinical Science</i> , <b>2016</b> , 130, 2139-2149	6.5	8
86	Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 251-60	15.1	90
85	The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. <i>Netherlands Heart Journal</i> , <b>2016</b> , 24, 259-67	2.2	28

84	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. <i>PLoS ONE</i> , <b>2016</b> , 11, e0167582	3.7	19
83	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 130-8	1.9	23
82	Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2449-56	15.1	132
81	Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 385-92	12.3	39
80	p-SMAD2/3 and DICER promote pre-miR-21 processing during pressure overload-associated myocardial remodeling. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2015</b> , 1852, 1520-30	6.9	30
79	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 764-71	12.3	73
78	Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 180-8	7.9	105
77	Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study. <i>Free Radical Biology and Medicine</i> , <b>2015</b> , 81, 1-12	7.8	20
76	Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. <i>Biomaterials</i> , <b>2014</b> , 35, 143-51	15.6	68
75	Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. <i>Scandinavian Cardiovascular Journal</i> , <b>2014</b> , 48, 299-303	2	14
74	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF- $\beta$ up-regulation. <i>Clinical Science</i> , <b>2014</b> , 126, 497-506	6.5	74
73	Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. <i>Hypertension</i> , <b>2014</b> , 63, 483-9	8.5	39
72	Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. <i>Journal of Cardiovascular Medicine</i> , <b>2014</b> , 15, 463-9	1.9	22
71	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , <b>2013</b> , 12, 143	8.7	24
70	T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. <i>Circulation: Cardiovascular Imaging</i> , <b>2013</b> , 6, 415-22	3.9	158
69	A synthetic peptide from transforming growth factor- $\beta$ type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats. <i>Antioxidants and Redox Signaling</i> , <b>2013</b> , 19, 1607-18	8.4	14
68	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 587-94	1.9	12
67	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 1239-49	7.6	183

66	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. <i>Cardiovascular Research</i> , <b>2013</b> , 99, 111-20	9.9	83
65	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. <i>Clinical Science</i> , <b>2013</b> , 125, 291-300	6.5	10
64	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. <i>Cardiovascular Ultrasound</i> , <b>2012</b> , 10, 10	2.4	58
63	Blockade of TGF- $\beta$ signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2012</b> , 2012, 726940	6.7	14
62	Cardiotrophin-1 in hypertensive heart disease. <i>Endocrine</i> , <b>2012</b> , 42, 9-17	4	20
61	Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. <i>Hypertension</i> , <b>2012</b> , 60, 677-83	8.5	118
60	New targets to treat the structural remodeling of the myocardium. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1833-43	15.1	129
59	Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 17-26	1.9	55
58	Towards the molecular diagnosis of hypertensive heart disease?. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 660-2.9		1
57	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , <b>2011</b> , 32, 177-83	9.5	16
56	Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2010</b> , 299, H1-9	5.2	177
55	Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. <i>Hypertension</i> , <b>2010</b> , 55, 1418-24	8.5	89
54	Association between left ventricular mass and telomere length in a population study. <i>American Journal of Epidemiology</i> , <b>2010</b> , 172, 440-50	3.8	46
53	Circulating biomarkers of collagen metabolism in cardiac diseases. <i>Circulation</i> , <b>2010</b> , 121, 1645-54	16.7	168
52	Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 552-63	59.2	452
51	Prevalence of left ventricular diastolic dysfunction in a general population. <i>Circulation: Heart Failure</i> , <b>2009</b> , 2, 105-12	7.6	233
50	Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. <i>Hypertension</i> , <b>2009</b> , 53, 236-42	8.5	120
49	Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2009</b> , 62, 305-13	0.7	2

48	Identification of a coronary vascular progenitor cell in the human heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 15885-90	11.5	170
47	La genética y la proteómica en la investigación de la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , <b>2009</b> , 62, 305-313	1.5	2
46	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 418-24	1.9	39
45	A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. <i>Cardiovascular Research</i> , <b>2009</b> , 81, 601-9	9.9	75
44	Biochemical markers of myocardial remodelling in hypertensive heart disease. <i>Cardiovascular Research</i> , <b>2009</b> , 81, 509-18	9.9	57
43	Renin-Angiotensin-Aldosterone System and Cardiomyocyte Apoptosis in Hypertensive Heart Disease <b>2009</b> , 143-150		1
42	Notch1 regulates the fate of cardiac progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 15529-34	11.5	169
41	Formation of large coronary arteries by cardiac progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 1668-73	11.5	142
40	Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. <i>Circulation Research</i> , <b>2008</b> , 102, 597-606	15.7	163
39	Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. <i>Kidney International</i> , <b>2008</b> , S19-23	9.9	33
38	Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 859-67	15.1	93
37	Avances en cardiopatía hipertensiva. Mecanismos de remodelado implicados en la transición de la hipertrofia a la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia Suplementos</i> , <b>2007</b> , 7, 14F-21F	0.2	
36	Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. <i>European Heart Journal</i> , <b>2007</b> , 28, 2785-91	9.5	27
35	Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. <i>Hypertension</i> , <b>2007</b> , 50, 977-83	8.5	40
34	The Role of Myocardial Collagen Network in Hypertensive Heart Disease. <i>Current Hypertension Reviews</i> , <b>2007</b> , 3, 1-7	2.3	5
33	Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 2148-57	1.9	40
32	Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). <i>Journal of Hypertension</i> , <b>2007</b> , 25, 1958-66	1.9	78
31	Bone marrow cells adopt the cardiomyogenic fate in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 17783-8	11.5	261



30	Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. <i>Cardiovascular Research</i> , <b>2006</b> , 69, 899-907	9.9	38
29	Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2006</b> , 290, H1503-9	5.2	62
28	Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 89-96	15.1	184
27	A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 2335-7	15.1	14
26	Angiotensin II and Myocardial Fibrosis, Clinical Implications <b>2006</b> , 193-213		
25	Apoptosis in hypertensive heart disease: a clinical approach. <i>Current Opinion in Cardiology</i> , <b>2006</b> , 21, 288-294	2.4	22
24	Remodeling in Hypertensive Heart Disease: Role of the Renin-Angiotensin-Aldosterone System <b>2006</b> , 177-189		
23	Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2005</b> , 2, 209-16		116
22	The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. <i>Journal of Hypertension</i> , <b>2005</b> , 23, 1445-51	1.9	58
21	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. <i>Journal of Hypertension</i> , <b>2005</b> , 23, 625-32	1.9	60
20	New directions in the assessment and treatment of hypertensive heart disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2005</b> , 14, 428-34	3.5	12
19	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. <i>Journal of Hypertension</i> , <b>2005</b> , 23, 2297-304	1.9	36
18	Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. <i>Circulation</i> , <b>2004</b> , 110, 1263-8	16.7	320
17	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. <i>Medical Clinics of North America</i> , <b>2004</b> , 88, 83-97	7	74
16	Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 2028-35	15.1	204
15	Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2004</b> , 13, 197-204	3.5	34
14	Cardiomyocyte apoptosis in hypertensive cardiomyopathy. <i>Cardiovascular Research</i> , <b>2003</b> , 59, 549-62	9.9	81
13	Involvement of cardiomyocyte survival-apoptosis balance in hypertensive cardiac remodeling. <i>Expert Review of Cardiovascular Therapy</i> , <b>2003</b> , 1, 293-307	2.5	7

12	The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. <i>Journal of Hypertension</i> , <b>2003</b> , 21, 2085-92	1.9	10
11	Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. <i>Circulation</i> , <b>2002</b> , 105, 2512-7	16.7	489
10	Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. <i>Hypertension</i> , <b>2002</b> , 39, 75-80	8.5	89
9	Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2002</b> , 34, 1585-93	5.8	93
8	Myocardial fibrosis in arterial hypertension. <i>European Heart Journal Supplements</i> , <b>2002</b> , 4, D18-D22	1.5	2
7	Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. <i>Circulation</i> , <b>2001</b> , 104, 286-91	16.7	214
6	Biochemical assessment of myocardial fibrosis in hypertensive heart disease. <i>Hypertension</i> , <b>2001</b> , 38, 1222-6	8.5	143
5	Effects of antihypertensive agents on the left ventricle: clinical implications. <i>American Journal of Cardiovascular Drugs</i> , <b>2001</b> , 1, 263-79	4	18
4	Clinical aspects of hypertensive myocardial fibrosis. <i>Current Opinion in Cardiology</i> , <b>2001</b> , 16, 328-35	2.1	106
3	Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. <i>Hypertension</i> , <b>2000</b> , 36, 1065-71	8.5	49
2	Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. <i>Journal of Hypertension</i> , <b>1998</b> , 16, 863-70	1.9	12
1	Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?. <i>Journal of Hypertension</i> , <b>1997</b> , 15, 1159-65	1.9	11